Top five 2024 clichés in cardiology (updated, and counting):

- “Difficult to cover this topic in x minutes” (x can be 5, 10, 20 minutes or three days, they will say it anyway)
- “Great talk, congratulations for staying on time” (which, I mean, should be normal)
- 'Did you have a…

The special #EuroPCR 2024 issue of EuroIntervention is online, and there is something to suit everyone's taste. Here are some of the questions addressed or discussed this week.

Invasive management and decision making
· Did sex modify the outcomes of the ISCHEMIA trial?
· Can…

The identification and management of patients at high bleeding risk (HBR) undergoing TAVI are of major importance, but the lack of standardised definitions is challenging for trial design, data interpretation, and clinical decision-making.

The Valve Academic Research Consortium…

There are three major late-breaking trials presented this year at #EuroPCR (May 15, 8.30-10.00 AM CEST).

The first trial is called REC-CAGEFREE II. It is the first randomized study of antiplatelet monotherapy after PCI with drug-coated balloons. It will test a stepwise regimen…

In this multicenter registry of 10,872 patients undergoing TAVI, baseline ejection fraction was ≤30% in 914 (8.4%) patients. Of them, the left ventricle recovered in 59.5%, including 26.7% patients whose left ventricle function normalized completely.

No recovery was associated…

#EuroPCR 2024 is fast approaching and to prepare for the Course, this year we have prepared the #EIJchallenge , which will put your knowledge of the journal and cardiovascular medicine to the test.

It will unfold in 2 parts: an online challenge on social media (Level 1) and then…

What is the optimal antiplatelet regimen in patients with ACS undergoing PCI who are at both high bleeding and ischemic risks (i.e., “birisk”)?

In the double-blind, randomized OPT-BIRISK trial, including 7758 PCI-treated birisk patients with ACS who completed 9 to 12 months of…

Complete revascularization is now 'a must' in ACS, but the optimal timing remains a matter of controversy: immediate? Staged in-hospital? Staged within 45 days? Staged when you want?

This prespecified analysis of the randomized BIOVASC trial suggests that immediate complete…

I am passionate about neutral studies, but only when their results are true negatives, not false negatives due to low statistical power. I particularly appreciate them when they eliminate drugs with seemingly routine indications but are actually poorly supported by literature or…

In this new state-of-the-art article, the authors summarize the rationale for renal denervation, review the available evidence, provide recommendations for a safe procedure, and discuss the role of renal denervation in current guidelines and clinical practice.…

In this study, the use of large language models and particularly ChatGPT-4 showed high agreement rate of 77% with the decision of the Heart Team regarding the management of severe aortic stenosis.

The authors discuss that integration of artificial intelligence in routine…

Over the last three days, we’ve seen almost all pharmacological strategies presented at #ACC24 fail, including beta blockers, which seemed like the only certainty. On the contrary, if we are to believe in the results we've seen, we should start using more microaxial flow pump…

After 10 years to complete it, the DanGer-SHOCK trial showed that the routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone.

The…